Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.

AUTOR(ES)

Thadepalli, H

RESUMO

Difloxacin (A-56619) and A-56620, two novel fluoroquinolones, were tested in comparison with ciprofloxacin, cefoxitin, and combined clindamycin and gentamicin in the treatment of experimentally induced intraabdominal abscess associated with Bacteroides fragilis. Difloxacin was found to be as effective as clindamycin-gentamicin. A-56620, despite achieving subtherapeutic levels in serum, was found to be as effective as cefoxitin. Both difloxacin and A-56620 were effective in vivo against experimentally induced intra-abdominal abscess in rats.

Documentos Relacionados

• Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitro.
• Microbial synergy in experimental intra-abdominal abscess.
• Postappendectomy intra-abdominal abscess: a therapeutic approach.
• Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis.
• Aryl-fluoroquinolone derivatives A-56619 (difloxacin) and A-56620 inhibit mitogen-induced human mononuclear cell proliferation.